These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cardiac actions of antihistamines. Woosley RL Annu Rev Pharmacol Toxicol; 1996; 36():233-52. PubMed ID: 8725389 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic overview of oral second-generation H1 antihistamines. González MA; Estes KS Int J Clin Pharmacol Ther; 1998 May; 36(5):292-300. PubMed ID: 9629995 [TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Hey JA; del Prado M; Sherwood J; Kreutner W; Egan RW Arzneimittelforschung; 1996 Feb; 46(2):153-8. PubMed ID: 8720304 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children. Delgado LF; Pferferman A; Solé D; Naspitz CK Ann Allergy Asthma Immunol; 1998 Apr; 80(4):333-7. PubMed ID: 9564984 [TBL] [Abstract][Full Text] [Related]
7. Public health problems and the rapid estimation of the size of the population at risk. Torsades de pointes and the use of terfenadine and astemizole in The Netherlands. Herings RM; Stricker BH; Leufkens HG; Bakker A; Sturmans F; Urquhart J Pharm World Sci; 1993 Oct; 15(5):212-8. PubMed ID: 8257958 [TBL] [Abstract][Full Text] [Related]
8. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental animal model of torsade de pointes. Hey JA; del Prado M; Kreutner W; Egan RW Arzneimittelforschung; 1996 Feb; 46(2):159-63. PubMed ID: 8720305 [TBL] [Abstract][Full Text] [Related]
9. [The effect of second generation histamine antagonists on the heart]. Grzelewska-Rzymowska I; Pietrzkowicz M; Górska M Pneumonol Alergol Pol; 2001; 69(3-4):217-26. PubMed ID: 11575008 [TBL] [Abstract][Full Text] [Related]
10. Is QT interval prolongation harmful? A regulatory perspective. Botstein P Am J Cardiol; 1993 Aug; 72(6):50B-52B. PubMed ID: 8256756 [TBL] [Abstract][Full Text] [Related]
11. Combined use of astemizole and ketoconazole resulting in torsade de pointes. Tsai WC; Tsai LM; Chen JH J Formos Med Assoc; 1997 Feb; 96(2):144-6. PubMed ID: 9071844 [TBL] [Abstract][Full Text] [Related]
12. Safety of antihistamines in children. Ten Eick AP; Blumer JL; Reed MD Drug Saf; 2001; 24(2):119-47. PubMed ID: 11235817 [TBL] [Abstract][Full Text] [Related]
13. Predictors of torsades de pointes in rabbit ventricles perfused with sedating and nonsedating histamine H1-receptor antagonists. Gilbert JD; Cahill SA; McCartney DG; Lukas A; Gross GJ Can J Physiol Pharmacol; 2000 May; 78(5):407-14. PubMed ID: 10841436 [TBL] [Abstract][Full Text] [Related]
14. Torsades de pointes occurring in association with terfenadine use. Monahan BP; Ferguson CL; Killeavy ES; Lloyd BK; Troy J; Cantilena LR JAMA; 1990 Dec; 264(21):2788-90. PubMed ID: 1977935 [TBL] [Abstract][Full Text] [Related]
16. Torsade de pointes induced by terfenadine in a patient with long QT syndrome. Koh KK; Rim MS; Yoon J; Kim SS J Electrocardiol; 1994 Oct; 27(4):343-6. PubMed ID: 7815014 [TBL] [Abstract][Full Text] [Related]
17. Drug-induced torsades de pointes in one patient with congenital long QT syndrome. Hsieh MH; Chen SA; Chiang CE; Tai CT; Lee SH; Wen ZC; Chang MS Int J Cardiol; 1996 Apr; 54(1):85-8. PubMed ID: 8792191 [TBL] [Abstract][Full Text] [Related]
19. Torsades de pointes ventricular tachycardia associated with overdose of astemizole. Rao KA; Adlakha A; Verma-Ansil B; Meloy TD; Stanton MS Mayo Clin Proc; 1994 Jun; 69(6):589-93. PubMed ID: 8189766 [TBL] [Abstract][Full Text] [Related]
20. Torsades de pointes from terfenadine and sotalol given in combination. Feroze H; Suri R; Silverman DI Pacing Clin Electrophysiol; 1996 Oct; 19(10):1519-21. PubMed ID: 8904547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]